Integra LifeSciences Provides Updated Plans To Restart The Manufacture Of Primatrix And Surgimend At Its New Manufacturing Facility In Braintree, Massachusetts

7/15/24 8:09:52 AM ET

Medical/Dental Instruments

Health Care

Get the next $IART alert in real time by email

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is announcing its plans to restart the manufacture of PriMatrix® and SurgiMend® at its new manufacturing facility in Braintree, Massachusetts. The Company expects to operationalize this new facility in the first half of 2026.

Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in March, the Company has been thoroughly reassessing its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site. In parallel, the Company has been furthering its plans to complete the construction and operationalization of its new state-of-the-art tissue manufacturing facility in Braintree. Based on these assessments, the Company no longer plans to restart the manufacture of these products at its Boston facility and will, instead, restart manufacturing of these products at the Braintree site.

Get the next $IART alert in real time by email

Date	Price Target	Rating	Analyst
10/7/2024		Sell → Neutral	BTIG Research
7/30/2024	$22.00	Neutral → Sell	BTIG Research
7/30/2024	$30.00 → $23.00	Neutral → Sell	Citigroup
5/7/2024		Outperform → Perform	Oppenheimer
5/7/2024	$45.00 → $25.00	Overweight → Equal Weight	Wells Fargo
4/3/2024	$38.00	Sell → Neutral	Citigroup
12/5/2023	$40.00 → $49.00	Equal Weight → Overweight	Wells Fargo
11/14/2023	$50.00	Buy	CL King

Integra LifeSciences Provides Updated Plans To Restart The Manufacture Of Primatrix And Surgimend At Its New Manufacturing Facility In Braintree, Massachusetts

Chat with this insight

Recent Analyst Ratings for $IART

$IART Leadership Updates

Live Leadership Updates

Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Alltrna Announces Updates to Its Board of Directors

$IART Financials

Live finance-specific insights

Integra LifeSciences Reports Third Quarter 2024 Financial Results

Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024

Integra LifeSciences Reports Second Quarter 2024 Financial Results

$IART SEC Filings

SEC Form S-8 filed by Integra LifeSciences Holdings Corporation

SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IART Market Insights

Live Market Insights

Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $32

8 Analysts Have This To Say About Integra Lifesciences

Morgan Stanley Maintains Underweight on Integra Lifesciences, Raises Price Target to $27

$IART Press Releases

Fastest customizable press release news feed in the world

Integra LifeSciences Reports Third Quarter 2024 Financial Results

Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024

$IART Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$IART Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

Integra upgraded by BTIG Research

Integra downgraded by BTIG Research with a new price target

Integra downgraded by Citigroup with a new price target

$IART Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

$IART Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President & CEO De Witte Jan covered exercise/tax liability with 4,262 shares and converted options into 9,814 shares, increasing direct ownership by 30% to 23,902 units (SEC Form 4)

EVP & CHRO Veillon-Berteloot Chantal covered exercise/tax liability with 1,412 shares, decreasing direct ownership by 5% to 24,379 units (SEC Form 4)

SVP, Fin & Princ Acct Officer Mosebrook Jeffrey sold $25,701 worth of shares (1,191 units at $21.58), decreasing direct ownership by 3% to 36,088 units (SEC Form 4)

Recent Analyst Ratings for
$IART

$IART
Leadership Updates

$IART
Financials

$IART
SEC Filings

$IART
Market Insights

$IART
Press Releases

$IART
Insider Purchases

$IART
Analyst Ratings

$IART
Large Ownership Changes

$IART
Insider Trading